Somatic hypermutation and class switching in autoimmunity
Somatic hypermutation and class switching in autoimmunity
批准号:
8775571
负责人:
Paolo Casali
金额:
$36.89万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-12-15 至 2014-11-30
关键词:
AblationAddressAffinityAntibodiesAntibody AffinityAntibody FormationAntigensAscaridilAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmunityB-LymphocytesBase Excision RepairsBindingBinding SitesBiochemicalBiologicalBypassCell divisionChromatinDNADNA Double Strand BreakDNA RepairDNA biosynthesisDNA lesionDNA-Directed DNA PolymeraseDataDeaminationDevelopmentDiamondElementsEstrogen ReceptorsEstrogensEvolutionGenerationsGenesGenetic RecombinationGenomeGoalsHealthHistonesHomeodomain ProteinsHumanHuman bodyIgEImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin Constant RegionImmunoglobulin GImmunoglobulin MImmunoglobulin Somatic HypermutationImmunoglobulinsInflammatory ResponseInjuryInterventionLeadLightLupusLymphoidMediatingMethodsMismatch RepairMolecularMusMutant Strains MiceMutationNatureOrganPatientsPeripheralPhasePlayPoint MutationPolymeraseProcessProteinsReceptors, Antigen, B-CellRecruitment ActivityRegulationResidual stateResolutionRoleSiteStagingSystemic Lupus ErythematosusTNFRSF5 geneTNFSF5 geneTestingTherapeuticTissuesUp-Regulationactivation-induced cytidine deaminasebasecytokineimmunopathologyinsightlupus prone micemicrobialmicroorganism antigenmutantpathogenpromoterrepairedresearch studyresponsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We want to understand the molecular mechanisms that underlie antibody somatic hypermutation (SHM) and class switch DNA recombination (CSR) in systemic autoimmunity, particularly systemic lupus. Like antibodies to microbial pathogens, most pathogenic autoantibodies are somatically hypermutated and class-switched. SHM introduces mainly point-mutations in immunoglobulin (Ig) heavy and light chain V(D)J regions, thereby providing the substrate for selection by (self) antigen of higher affinity (auto)antibody mutants. CSR replaces the expressed IgH constant (CH) region, e.g., C5, with downstream C3, C1 or C5, thereby endowing (auto)antibodies with new biological effector functions. Both SHM and CSR entail two sequential stages: (i) generation of DNA lesions, as mediated by activation-induced cytidine-deaminase (AID), and (ii) DNA lesion repair by the basic site bypass, base-excision repair (BER) or mismatch repair (MMR) machineries, leading to the emergence of mismatches (SHM) or double-strand DNA breaks (DSBs) and their resolution (CSR). We argue here that in systemic lupus, SHM and CSR are dysregulated, as a result of upregulated AID and, therefore, increased DNA lesions, and altered DNA repair. We contend that the phylogenetically conserved homeodomain protein HoxC4, which, as we have shown, critically regulates SHM and CSR, induces AID expression by directly binding to a conserved HoxC4/Oct-binding 5'-ATTTGAAT-3' site we have identified in the AID promoter. We also contend that estrogen greatly enhances CD154:CD40-induced HoxC4 expression by triggering the binding of estrogen receptors (ERs) to two conserved estrogen responsive elements (EREs) we have recently identified in the HoxC4 promoter, thereby further enhancing AID expression and contributing to SHM/CSR dysregulation in lupus. We also argue that the translesion DNA synthesis (TLS) polymerase (pol) 8 and pol7 are critical in SHM of (auto)antibodies, by repairing DNA lesions after being recruited by ubiquitinated PCNA, which mediates the "polymerase switch" from high-fidelity replicative DNA polymerases to error-prone TLS polymerases. Finally, we hypothesize that expression of HoxC4, AID and TLS polymerases is dysregulated in lupus-prone mice and ablation of HoxC4, Ung or TLS pol7 leads to decreased SHM/CSR and, therefore, decreased level of high-affinity and isotype-switched autoantibodies and delayed immunopathology. To test our hypotheses, we will: (i) define the molecular mechanisms of HoxC4-mediated AID promoter activation and the enhancement of HoxC4 and, therefore, AID expression by estrogen; (ii) address the role of TLS pol8 and pol7 and their recruitment by ubiquitinated PCNA in SHM; and, finally, (iii) analyze the SHM/CSR dysregulation and the impact of deficiency of HoxC4, Ung org pol7 on the generation of hypermutated and class-switched autoantibodies in lupus-prone mice. These experiments will use sophisticated biochemical methods and our new KO HoxC4-/-, pol8-/-, double KO pol8-/-Ung-/- and pol7-/-Ung-/- and mutant Aicdatm1(Pmut) and pol7mut mice, and lupus-prone MRL/Faslpr/lpr mice deficient in HoxC4, Ung or pol7.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetics of the autoantibody response in systemic lupus
-
批准号:10494251
-
项目类别:
-
资助金额:$71.08万
-
财政年份:2021
-
负责人:Paolo Casali
-
依托单位:
Epigenetics of the autoantibody response in systemic lupus
-
批准号:10392220
-
项目类别:
-
资助金额:$73.33万
-
财政年份:2021
-
负责人:Paolo Casali
-
依托单位:
Epigenetics of the autoantibody response in systemic lupus
-
批准号:10681392
-
项目类别:
-
资助金额:$71.08万
-
财政年份:2021
-
负责人:Paolo Casali
-
依托单位:
Epigenetic downregulation of the antibody and autoantibody response
-
批准号:9198631
-
项目类别:
-
资助金额:$4.82万
-
财政年份:2014
-
负责人:Paolo Casali
-
依托单位:
Epigenetic downregulation of the antibody and autoantibody response
-
批准号:8996116
-
项目类别:
-
资助金额:$41.42万
-
财政年份:2014
-
负责人:Paolo Casali
-
依托单位:
Epigenetic downregulation of the antibody and autoantibody response
-
批准号:9205214
-
项目类别:
-
资助金额:$47.32万
-
财政年份:2014
-
负责人:Paolo Casali
-
依托单位:
Epigenetic downregulation of the antibody and autoantibody response
-
批准号:8639370
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2014
-
负责人:Paolo Casali
-
依托单位:
Epigenetic downregulation of the antibody and autoantibody response
-
批准号:8794403
-
项目类别:
-
资助金额:$41.42万
-
财政年份:2014
-
负责人:Paolo Casali
-
依托单位:
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
-
批准号:10335163
-
项目类别:
-
资助金额:$47.44万
-
财政年份:2013
-
负责人:Paolo Casali
-
依托单位:
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
-
批准号:10544531
-
项目类别:
-
资助金额:$47.44万
-
财政年份:2013
-
负责人:Paolo Casali
-
依托单位:
Epigenetic downregulation of the antibody response and inhibition of autoimmunity
-
批准号:8658530
-
项目类别:
-
资助金额:$28.64万
-
财政年份:2013
-
负责人:Paolo Casali
-
依托单位:
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
-
批准号:10090553
-
项目类别:
-
资助金额:$47.44万
-
财政年份:2013
-
负责人:Paolo Casali
-
依托单位:
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
-
批准号:9765935
-
项目类别:
-
资助金额:$48.74万
-
财政年份:2013
-
负责人:Paolo Casali
-
依托单位:
Immunoglobulin class switch DNA recombination
-
批准号:8513563
-
项目类别:
-
资助金额:$52.26万
-
财政年份:2012
-
负责人:Paolo Casali
-
依托单位:
14-3-3 ADAPTOR PROTEINS RECRUIT AID TO 5'-AGCT-3'-RICH SWITCH REGIONS
-
批准号:8365797
-
项目类别:
-
资助金额:$1.28万
-
财政年份:2011
-
负责人:Paolo Casali
-
依托单位:
Somatic hypermutation and class switching in autoimmunity
-
批准号:8391258
-
项目类别:
-
资助金额:$35.6万
-
财政年份:2009
-
负责人:Paolo Casali
-
依托单位:
Somatic hypermutation and class switching in autoimmunity
-
批准号:7792737
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2009
-
负责人:Paolo Casali
-
依托单位:
Rab7 and estrogen-ER as B cell-intrinsic mediators of auto/antibody responses
-
批准号:9185922
-
项目类别:
-
资助金额:$44.4万
-
财政年份:2009
-
负责人:Paolo Casali
-
依托单位:
Somatic hypermutation and class switching in autoimmunity
-
批准号:8196955
-
项目类别:
-
资助金额:$37.87万
-
财政年份:2009
-
负责人:Paolo Casali
-
依托单位:
Somatic hypermutation and class switching in autoimmunity
-
批准号:8004087
-
项目类别:
-
资助金额:$37.87万
-
财政年份:2009
-
负责人:Paolo Casali
-
依托单位:
海外基金